Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036341 (schizophrenia)
 60,220 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The frequency of affective symptoms in most descriptions of premenstrual syndromes (PMS) suggests a potential etiologic link between menstrually-related mood changes and specific psychiatric disorders. The purpose of this study is to assess women presenting with "PMS" for lifetime psychiatric illness and PMS, according to rigorous diagnostic criteria comparable to those for "late luteal phase disorder," a proposed DSM-III-R diagnosis requiring further study. The women were interviewed with the Schedule for Affective Disorders and Schizophrenia Lifetime Version (SADS-L) and they kept prospective records of menstrual symptoms with the Moos Menstrual Distress Questionnaire - Form T (Moos MDQ-T). Of the 20 women evaluated, 85% had lifetime psychiatric illness and 30% had PMS. Careful psychiatric assessment is recommended in patients presenting with "PMS" as their chief complaint.
Conn Med 1991 Dec
PMID:Lifetime psychiatric illness and premenstrual syndromes. 179 Jul 5

The author reports the results of five studies of panic disorder undertaken as part of the Epidemiologic Catchment Area Program of the National Institute of Mental Health (NIMH). This program involves community samples in New Haven, Conn. (N = 5,034), Baltimore (N = 3,481), St. Louis (N = 3,004), Durham, N.C. (N = 3,921), and Los Angeles (N = 3,132). Diagnoses were based on the NIMH Diagnostic Interview Schedule and DSM-III. Panic disorder led the list of disorders for which subjects in the five studies received ambulatory mental health services. Treatment rates for panic disorder were as high as or higher than those for somatization disorder, schizophrenia, and major affective disorders. Furthermore, panic attacks may have been the reason that many subjects with other disorders sought treatment.
 ...
PMID:Use of mental health services for the treatment of panic disorder. 378 10

Data from diverse sources suggest that psychotherapy works by changing the functioning of the brain. This observation is part of a larger phenomenon involving neural plasticity. An extraordinary amount of research is demonstrating that neither gene expression nor the anatomy or physiology of the brain is static. Environment and genetics are in an ongoing interaction with one another, and this mutual influence informs our latest understanding of how psychotherapy appears to affect brain functioning. Research on disorders such as schizophrenia, obsessive-compulsive disorder, cancer, and panic disorder provide convincing data in this regard. For a full understanding of the etiology and pathogenesis of mental illness, as well as its treatment, the psychodynamic dimension of meaning must be incorporated.
Conn Med 1997 Sep
PMID:Dynamic therapy in the decade of the brain. 933 8

This paper reviews the current clinical use of psychotropic drugs and suggests new directions for future drug development. The author reviews the contemporary pharmacotherapy of depression, anxiety disorders, schizophrenia, and bipolar disorder and summarizes current trends in the drug treatment of psychiatric aspects of HIV disease. The increasing use of combination pharmacotherapy is discussed, as well as the impact of pharmacokinetics in clinical psychopharmacology. The use of botanical products for psychiatric disorders and tobacco use in the psychiatric patient are also addressed. Current research is producing drugs that have greater specificity in their mechanism of action effecting faster clinical response with minimum adverse effects.
Conn Med 1997 Sep
PMID:New directions in clinical psychopharmacology. 933 14

The Schizophrenia Rehabilitation Center at the Institute of Living has begun to develop rehabilitation techniques based on a neuropsychological approach to ameliorate the cognitive deficits associated with schizophrenia. A study was designed to test the hypothesis that patients receiving attention skills training would demonstrate improved performance on neuropsychological tests measuring concentration. Five out of the seven subjects significantly improved on more than half of the neuropsychological measures. In the two case studies reviewed, significant increases in test scores were observed more frequently during cognitive rehabilitation then when psychoeducation classes were substituted for the attention skills training. In addition, patients showed improvement on the Positive and Negative Syndrome Scale and Quality of Life Scale. The data support the efficacy of attention skills training using a process specific approach. However, it is uncertain if attention skills rehabilitation is a necessary or sufficient factor in producing the therapeutic change.
Conn Med 1997 Sep
PMID:Neuropsychological rehabilitation in the treatment of schizophrenia. 933 15

Dr Conn is the Lee E Limbird Professor of Pharmacology at Vanderbilt University and Director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). Dr Conn received a PhD in Pharmacology from Vanderbilt in 1986 and pursued postdoctoral studies at Yale University. He served as a professor of Pharmacology at Emory University from 1988 to 2000, before moving to Merck and Co. (PA, USA) as head of the Department of Neuroscience. Dr Conn moved to Vanderbilt University in 2003 where he is the founding director of the VCNDD, with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. The VCNDD consists of approximately 100 full-time scientists and has advanced novel molecules from four major programs as development candidates for clinical testing with industry partners. Dr Conn has served in editorial positions with multiple international journals and has served the scientific advisory boards of multiple foundations and companies. He has received numerous awards based on the impact of his basic and translational research. Dr Conn's current research is focused on development of novel treatment strategies for schizophrenia, Parkinson's disease and other serious brain disorders. Interview conducted by Hannah Coaker, Assistant Commissioning Editor.
...
PMID:Interview: interview with P Jeffrey Conn. Interview by Hannah Coaker. 2402 42

Electroconvulsive therapy (ECT) is an effective treatment for many psychiatric illnesses including refractory depression, catatonia, bipolar disorder, and schizophrenia, along with neuropsychiatric diseases such as dementia and Parkinson's disease. The emergence of a seizure disorder after the initiation of ECT is a rare but severe occurrence. It can become challenging for clinicians to determine whether ECT should be continued. We present a case of a 73-year-old female with schizoaffective disorder who received a total of 173 ECT treatments over the course of five years for breakthrough psychosis due to medication nonadherence. After five years of treatment, she experienced her first episode of tonic-clonic seizure activity. We review the current evidence and discuss factors that should be considered when treating such an individual.
Conn Med 2016 Sep
PMID:New Onset Seizure Disorder Following Electroconvulsive Therapy. 2978 84